Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude

NCT ID: NCT03588676

Last Updated: 2019-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-10
• Study Completion Date: 2018-12-10

Brief Summary

Low oxygen at altitude causes pauses in breathing during sleep, called central sleep apnea. Central sleep apnea causes repeated awakenings and poor sleep. Low oxygen itself and the induced oxidative stress can damage mental function which is likely worsened by poor sleep. Reduced mental function due to low oxygen can pose a serious danger to mountain climbers. However there is also mounting evidence that even in populations of people that live at high altitudes and are considered adapted, low oxygen contributes to reductions in learning and memory. Therefore there is a serious need for treatments which may improve sleep, control of breathing and mental function during low oxygen.Therefore this study aims to determine how melatonin effects control of breathing, sleep and mental performance during exposure to low oxygen.

Detailed Description

Research has shown that exposure to low oxygen at altitude causes neurocognitive impairment (impaired mental processing, memory, attention, learning, etc). This impairment in cognitive performance poses a serious risk to mountain climbers and while it has traditionally been thought that people who live at high altitude have adapted to it, evidence shows there is still considerable damage to the brain and impairments in cognitive function of people who live and work at high altitude.

As every cell in the body requires oxygen to survive and function, impairment in cognitive performance at altitude is thought mainly due to reduced oxygen availability to the central nervous system. However, low oxygen at altitude also causes unstable breathing during sleep which results in short periods where the brain stops sending the signal to breath, called central sleep apnea (CSA). During apneas (pauses in breathing) blood oxygen drops even lower and people typically wake up briefly and hyperventilate after apneas. Therefore at altitude people usually get less sleep, their sleep is broken with periods of wakefulness during the night and they experience repeated bouts of severe low blood oxygen levels. Sleep plays a critical role in how the brain repairs and also converts newly acquired information into long-term memory. Therefore broken and reduced sleep can impair cognitive performance, memory and learning. Repeated bouts of severe low oxygen also produces highly reactive molecules that cause damage to cells, called oxidative stress. Oxidative stress also prevents the brain from forming long-term memories and in severe cases (such as extremely high altitude and long duration exposure) can cause neurons in the brain to die. Therefore although sustained low oxygen at altitude likely impairs cognitive function, disturbed sleep and repeated bouts of severely low oxygen likely also contribute to causing brain damage and impaired cognitive performance.

Melatonin is a hormone produced in the pineal gland of the brain during the night which signals to the brain that it is time to sleep. Melatonin is also a very powerful antioxidant which naturally helps to prevent damage in the body from oxidative stress. A study previously reported that melatonin taken 90 mins before bed at 4,300 m (14,200 ft) reduced the time taken to fall asleep, it reduced the number of times people woke up during sleep and improved cognitive performance the following day. However how melatonin caused these effects was not determined. Therefore this study aims to determine how melatonin affects ventilatory control, sleep and neurocognitive performance during sustained hypoxia.

Conditions

Intermittent Hypoxia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Normoxia

Participants will sleep in room air and receive no melatonin.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Hypoxia and Placebo

5mg placebo before sleep study

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

5mg Placebo capsule

Hypoxia and Melatonin

5mg melatonin before sleep study

Group Type: EXPERIMENTAL

Melatonin

Intervention Type: OTHER

5mg Melatonin

Interventions

Melatonin

5mg Melatonin

Intervention Type: OTHER

Placebo

5mg Placebo capsule

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Healthy Males and Females
• Age:18-65 years

Exclusion Criteria

• Sleep Disorders
• Pregnant Females
• Smokers (quit ≥ 1 year ago acceptable)
• Cardiovascular, Pulmonary, Renal, Neurologic, Neuromuscular, or Hepatic Issues
• Diabetes
• Psychiatric disorder, other than mild depression
• Recent exposure to altitude (>8000ft) in the last month or having slept at an altitude >6000ft in the last month

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Robert L. Owens

OTHER

Sponsor Role: lead

Responsible Party

Robert L. Owens

Associate Physician

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Atul Malhotra, MD

Role: PRINCIPAL_INVESTIGATOR

Professor

Naomi L Deacon, Ph.D.

Role: STUDY_DIRECTOR

Research Associate

Pamela De Young

Role: STUDY_CHAIR

Research Associate

Locations

University of California, San Diego

San Diego, California, United States

Countries

United States

Related Links

https://healthsciences.ucsd.edu/som/medicine/research/centers/sleep-research/research/active-studies/Pages/High-Altitude-and-Sleep.aspx

Study Website

Other Identifiers

UCSD170200

Identifier Type: -

Identifier Source: org_study_id